J Studios/DigitalVision via Getty Images I've been growing fond of Nuvation Bio Inc. ( NUVB ). At first, I was bearish, but it has since become apparent that its lead drug, Ibtrozi, is becoming a popular and, dare I say, “preferred” option in ROS1+ non-small cell lung cancer (ROS1+ NSCLC). My last analysis was in February (my rating was Hold ), and I modeled the drug in this indication and valued ...
J Studios/DigitalVision via Getty Images I've been growing fond of Nuvation Bio Inc. ( NUVB ). At first, I was bearish, but it has since become apparent that its lead drug, Ibtrozi, is becoming a popular and, dare I say, “preferred” option in ROS1+ non-small cell lung cancer (ROS1+ NSCLC). My last analysis was in February (my rating was Hold ), and I modeled the drug in this indication and valued it at $1.07 billion in net present value, generating roughly $440 million in peak annual sales. This reflected the niche market in ROS1+ NSCLC (~3,000 U.S. cases annually, just 1-2% of all NSCLC cases) and competition (other TKIs). At that time, Ibtrozi didn't appear to have a real edge over Bristol-Myers Squibb Company's ( BMY ) Augtyro. I thought that Ibtrozi provided the stock with a floor, or a fair price per share of between $4 and $5. So, I thought the stock was only moderately overvalued then, bearing in mind that the price at publication was $5.44 per share. With its stock dipping under $5 per share after its first-quarter earnings report, I wanted to take another look to see if NUVB merits a re-rating. Q1 Earnings Nuvation reported its first quarter earnings on May 4. Everything looked pretty solid. The company posted a net income of $5.4 million, good for an EPS of $0.01. Total revenue was $83.2 million, but a significant portion of this came from their licensing agreement with Eisai for Ibtrozi in Europe and other regions outside the U.S., China, and Japan. Specifically, net product revenue for Ibtrozi came in at $18.5 million. Management noted that 200 new patients were added in Q1, which brings the total to over 600 since it launched in June. Importantly, more than half of the Q1 starts were in TKI-naive patients. Recent Developments In April, Novation revealed longer-term pooled data from the TRUST-1 and TRUST-2 trials. The data focused specifically on the duration of response and response rates in TKI-naive patients. The median duration of response is of part...
Roman Tiraspolsky Blackstone ( BX ) is trying to sell more than $2B of stakes it owns in private investment funds in one of the largest deals of its kind, according to a media report. The size of the proposed transaction will test investors' interest in aging private equity vehicles. The private equity firm is marketing a collateralized fund obligation that will package more than $2B of stakes in ...
Roman Tiraspolsky Blackstone ( BX ) is trying to sell more than $2B of stakes it owns in private investment funds in one of the largest deals of its kind, according to a media report. The size of the proposed transaction will test investors' interest in aging private equity vehicles. The private equity firm is marketing a collateralized fund obligation that will package more than $2B of stakes in leveraged buyout funds into bonds to sell to investors and insurers, the Financial Times reported, citing people familiar with the matter. The deal, which would provide an inflow of cash to investors in a Blackstone Strategic Partner fund, which invests in other private equity groups' funds. It isn't clear whether Blackstone ( BX ) will proceed with the securitization or try to sell the fund stakes in a secondary transaction, one person told the FT . The company is still in the early marketing and structuring phase of the transaction. It's unclear if there will be demand for the equity tranche of the CFO, an equity tranche, a person familiar with the deal told the FT . Blackstone ( BX ) stock gained 0.7% in premarket trading. More on Blackstone Prologis: Likely To Outperform Blackstone Industrial Funds Blackstone: Be Greedy When Others Are Fearful A Rare Chance To Buy Blackstone's $1.3 Trillion Empire At A Deep Discount Blackstone-backed AirTrunk to invest $30B in India digital infrastructure Blackstone private credit fund latest to curb redemptions after surge in Q2 withdrawal requests
GomezDavid/iStock via Getty Images Electricity has become a hot investment theme in recent years. Electric vehicles and other such emerging technologies are providing a significant incremental source of grid demand. And that increase has accelerated recently thanks to power-hungry AI applications and their related data center facilities. Nuclear power has been well-positioned to tap into this newf...
GomezDavid/iStock via Getty Images Electricity has become a hot investment theme in recent years. Electric vehicles and other such emerging technologies are providing a significant incremental source of grid demand. And that increase has accelerated recently thanks to power-hungry AI applications and their related data center facilities. Nuclear power has been well-positioned to tap into this newfound demand for additional electricity generation. Nuclear stocks were particularly hot in 2025, with the benchmark VanEck Uranium and Nuclear ETF ( NLR ) jumping as much as 150% from the March 2025 lows. The demand for data centers seemed endless, and it seemed practically assured that this would turn into a massive boom for nuclear power companies. This thesis was logical enough. But at a certain valuation, even if things go according to plan, you can still end up with an investment that loses money. That appears to be playing out for nuclear power stocks now. AI infrastructure spending has continued to be insatiable through the first half of 2026. Yet, nuclear power stocks have seriously cooled off. The above-mentioned nuclear power ETF is now down 27% from the highs, including an 18% decline over the past month alone. And some individual names, such as Centrus Energy ( LEU ), are down a lot more than that. I had been bearish on Centrus Energy shares for much of the past year. However, as the below graphic shows, I did upgrade the stock to a hold with my prior article: Author prior LEU coverage (Seeking Alpha) In March 2026, I argued that Centrus' new partnerships and more reasonable valuation supported a neutral rather than bearish view. With the stock having underperformed the S&P 500 by another 34% since my most recent article, it's worth taking a fresh look at Centrus. Is the stock cheap enough to be worth considering here, or is it better to stay neutral for the time being? Centrus' Most Recent Earnings Centrus released its Q1 earnings on May 5th. The report was a m...
peshkov/iStock via Getty Images Broadcom ( AVGO ) closed at an all-time high on June 2 nd heading into their Q2 2026 earnings. The next day, AVGO reported one of the strongest quarters of any large cap this earnings season, and the market responded by erasing more than 1/5 th of its market cap over a 2-day period as shares fell from $495 to $385.73 (-22.08%). That works out to more than $400 billi...
peshkov/iStock via Getty Images Broadcom ( AVGO ) closed at an all-time high on June 2 nd heading into their Q2 2026 earnings. The next day, AVGO reported one of the strongest quarters of any large cap this earnings season, and the market responded by erasing more than 1/5 th of its market cap over a 2-day period as shares fell from $495 to $385.73 (-22.08%). That works out to more than $400 billion of market cap vaporized in two sessions for a company that just grew revenue 48% YoY , grew AI semiconductor revenue 143% YoY, and guided for a revenue increase of 84% YoY. In my opinion, the selloff wasn’t about AVGO’s quarter, as there were no blemishes; it was about the bar that was established. Management guided for its Q3 AI semiconductor revenue to come in at $16 billion, but the analyst community was modeling for this business segment to generate $17.3 billion in Q3. The kicker is that AVGO reiterated its 2027 fiscal year guidance for their AI revenue to exceed $100 billion, and it seems like the analyst community punished them for not raising guidance. I’m looking at the same print and coming to a different conclusion, as AVGO had over $30 billion of AI bookings in a single quarter against $10.8 billion shipped with order visibility extending throughout 2028. AVGO also signed multigeneration silicon and networking agreements with Alphabet ( GOOG ) ( GOOGL ), Meta Platforms ( META ), Anthropic ( ANTHRO ) , and OpenAI ( OPENAI ) that will last several years. I have been looking for an entry point for AVGO and once it fell under $410, I took the opportunity that presented itself. Nobody knows what will happen in the short term, but from a long-term valuation perspective, I am willing to pay the present value for all of AVGO’s future cash flows. Seeking Alpha Broadcom delivered record results in Q2 across every line that matters AVGO’s Q2 2026 results ended in a clean sweep with their revenue increasing 47.87% YoY to $22.19 billion. This was a beat on the top line by...
peshkov/iStock via Getty Images Broadcom ( AVGO ) closed at an all-time high on June 2 nd heading into their Q2 2026 earnings. The next day, AVGO reported one of the strongest quarters of any large cap this earnings season, and the market responded by erasing more than 1/5 th of its market cap over a 2-day period as shares fell from $495 to $385.73 (-22.08%). That works out to more than $400 billi...
peshkov/iStock via Getty Images Broadcom ( AVGO ) closed at an all-time high on June 2 nd heading into their Q2 2026 earnings. The next day, AVGO reported one of the strongest quarters of any large cap this earnings season, and the market responded by erasing more than 1/5 th of its market cap over a 2-day period as shares fell from $495 to $385.73 (-22.08%). That works out to more than $400 billion of market cap vaporized in two sessions for a company that just grew revenue 48% YoY , grew AI semiconductor revenue 143% YoY, and guided for a revenue increase of 84% YoY. In my opinion, the selloff wasn’t about AVGO’s quarter, as there were no blemishes; it was about the bar that was established. Management guided for its Q3 AI semiconductor revenue to come in at $16 billion, but the analyst community was modeling for this business segment to generate $17.3 billion in Q3. The kicker is that AVGO reiterated its 2027 fiscal year guidance for their AI revenue to exceed $100 billion, and it seems like the analyst community punished them for not raising guidance. I’m looking at the same print and coming to a different conclusion, as AVGO had over $30 billion of AI bookings in a single quarter against $10.8 billion shipped with order visibility extending throughout 2028. AVGO also signed multigeneration silicon and networking agreements with Alphabet ( GOOG ) ( GOOGL ), Meta Platforms ( META ), Anthropic ( ANTHRO ) , and OpenAI ( OPENAI ) that will last several years. I have been looking for an entry point for AVGO and once it fell under $410, I took the opportunity that presented itself. Nobody knows what will happen in the short term, but from a long-term valuation perspective, I am willing to pay the present value for all of AVGO’s future cash flows. Seeking Alpha Broadcom delivered record results in Q2 across every line that matters AVGO’s Q2 2026 results ended in a clean sweep with their revenue increasing 47.87% YoY to $22.19 billion. This was a beat on the top line by...
The race for no. 3 in obesity drugs just got tougher. At the American Diabetes Association meeting in New Orleans, market leader Eli Lilly & Co. asserted its dominance with data showing its next-generation shot, retatrutide, can help patients lose 30% of their body weight over about two years. Novo Nordisk A/S , the no. 2, said its new Wegovy obesity pill surpassed three million prescriptions. Som...
The race for no. 3 in obesity drugs just got tougher. At the American Diabetes Association meeting in New Orleans, market leader Eli Lilly & Co. asserted its dominance with data showing its next-generation shot, retatrutide, can help patients lose 30% of their body weight over about two years. Novo Nordisk A/S , the no. 2, said its new Wegovy obesity pill surpassed three million prescriptions. Some of the companies looking to challenge the leaders had a tougher time. Boehringer Ingelheim GmbH ’s survodutide was less competitive on weight loss and had high vomiting rates, data showed, sending shares of its Danish biotech licensee Zealand Pharma A/S down as much as 27% on Monday. A Roche Holding AG shot pitched as a gentler alternative lagged a similar drug from Lilly on efficacy, according to Bloomberg Intelligence analysts. Boehringer and Roche, along with AstraZeneca Plc , Pfizer Inc. and Amgen Inc. , are all pitching a future where patients and doctors choose an obesity treatment not only based on potential pounds lost. Convenience, the scale of side effects or better results on the plethora of conditions that accompany excess weight should also inform the choice. “We’ve got to change this from just a race to who can provide that biggest weight-loss number,” Brian Hilberdink , who leads Boehringer’s US human pharma unit, said in an interview. Their problem is that market heavyweights Lilly and Novo are also trying to fill the same niches. Novo is exploring whether its drugs could have a role in the buzzy area of life longevity, Chief Executive Officer Mike Doustdar told Bloomberg on Sunday. With billions of people living with overweight or obesity, it’s unreasonable to think that everyone will be satisfied with a single medicine, Ken Custer , president of Lilly’s cardiometabolic health unit, said in a company press program. “In the years to come we’re going to move from a one-size-fits-all approach,” he added. Read More: Novo CEO Looks Beyond Weight Loss to Longev...
Lordhenrivoton | E+ | Getty Images When people think of how much to save for retirement — and, subsequently, how to spend that money wisely in older age — many worry about the risk of running out of money early. They fear the possibility of overspending. But there's another less-appreciated danger, too, according to financial experts: The risk of underspending one's nest egg. "Overspending is risk...
Lordhenrivoton | E+ | Getty Images When people think of how much to save for retirement — and, subsequently, how to spend that money wisely in older age — many worry about the risk of running out of money early. They fear the possibility of overspending. But there's another less-appreciated danger, too, according to financial experts: The risk of underspending one's nest egg. "Overspending is risky. But underspending is risky too," said Zach Teutsch, a member of CNBC's Financial Advisor Council and founder of Values Added Financial in Washington. Data shows that it happens to many retirees. About a third of retirees still have 100% or more of their initial savings remaining by their mid-80s, according to a recent study by the Employee Benefit Research Institute, a nonpartisan research group. "When you see so many people into their 80s still at 100%, you see people who are being way too conservative [with their spending]," said Craig Copeland, the director of wealth benefits research at EBRI. Read more CNBC personal finance coverage More workers are raiding their 401(k)s as average balances fall, Fidelity says Roth IRA owners may need a second retirement account to claim the Saver's Match Millions of people lose food stamp access as 'big beautiful bill' cuts take effect Trump Accounts create a 'legal backdoor' for Roth IRA wealth, tax attorney says CNBC's Financial Advisor 100: Best financial advisors, top firms ranked Of course, the opposite is true, too: "You also see some people with less than 20% [of their assets remaining] who are in the other situation: 'If I live five more years, I won't be able to do anything,'" Copeland said. About a fifth of people who entered retirement with more than $500,000 had less than 20% of their assets remaining by their mid-80s, according to EBRI's research. "This will be the foremost challenge in retirement: figuring out how to maximize retirement but still have a buffer at the end," Copeland said. The risk of underspending Vgaji...
A holder who started Friday, June 5, 2026 with $10,000 in ProShares Ultra Technology (NYSEARCA:ROM) ended the day with about $8,655. The fund opened at $161.98 and closed at $140.20, a single-session loss of 13.45%. Over the same five trading days, ROM gave back 11.8%, with the week starting at $158.95. Those numbers are what ... Why ROM Holders Watched $10,000 Evaporate to $8,655 When NVIDIA and ...
A holder who started Friday, June 5, 2026 with $10,000 in ProShares Ultra Technology (NYSEARCA:ROM) ended the day with about $8,655. The fund opened at $161.98 and closed at $140.20, a single-session loss of 13.45%. Over the same five trading days, ROM gave back 11.8%, with the week starting at $158.95. Those numbers are what ... Why ROM Holders Watched $10,000 Evaporate to $8,655 When NVIDIA and Broadcom Stumbled on Friday
BlackJack3D Shares of Coinbase Global ( COIN ), along with other major crypto-linked equities, pushed higher in premarket trading on Monday as a sharp rebound in Bitcoin prices injected fresh bullish sentiment back into the digital asset sector. Among gainers, Strategy ( MSTR ) +4%, Coinbase Global ( COIN ) +3.2%, Circle Internet Group ( CRCL ) +3.7%, Galaxy Digital ( GLXY ) +2.9%, Bullish ( BLSH ...
BlackJack3D Shares of Coinbase Global ( COIN ), along with other major crypto-linked equities, pushed higher in premarket trading on Monday as a sharp rebound in Bitcoin prices injected fresh bullish sentiment back into the digital asset sector. Among gainers, Strategy ( MSTR ) +4%, Coinbase Global ( COIN ) +3.2%, Circle Internet Group ( CRCL ) +3.7%, Galaxy Digital ( GLXY ) +2.9%, Bullish ( BLSH ) +2%, Robinhood Markets ( HOOD ) +2.2%, MARA Holdings ( MARA ) +2.9%, Hut 8 ( HUT ) +4.2%, and Iren ( IREN ) +3.7%. Bitcoin rose as much as 3.8% to nearly $64,200 on Monday before easing to around $63,400 in early New York trading, while Ether gained up to 5.6% to about $1,720. Bitcoin steadied after dropping below the key threshold of $60,000, as Strategy ( MSTR ) Chairman Michael Saylor hinted at further purchases of the token. Saylor also attributed Bitcoin's ( BTC-USD ) recent selloff to a shift of investor capital into AI rather than any deterioration in the cryptocurrency's long-term fundamentals. However, the sustainability of the bounce is in question as spot ETF flows show institutions have been actively selling into this dip. This starkly contrasts with February, when they eased off selling as prices approached the same long-term moving average, as per a CoinDesk report. Some analysts said the selloff is likely to deepen to mid-$50,000, or even lower, if the average gives away. "If the mid-$50Ks fail to hold, the next backstop is the $48K–$52K range. At these prices, older legacy mining rigs begin generating negative daily net revenue," Jean-David Péquignot, the chief commercial officer at leading crypto options exchange Deribit, told CoinDesk. "A drop to this level forces inefficient miners to unplug, prompting natural supply-side capitulation and a downward reset in network difficulty. Historically, miner capitulation phases align with cyclical bottoms," Péquignot said. More on Coinbase, Hut 8 Mining, etc. BTC: Why Bitcoin May Be Bottoming Now, Levels To Watch ...